Note: Descriptions are shown in the official language in which they were submitted.
CA 02512847 2005-07-08
W02004/067574 - 1 - PCT/FR2004/000089
Conjugates obtained by reductive amination of serotype
pneumococcus capsular polysaccharide
The present invention relates especially to a
5 particular aminated form of the pneumococcus type 5
capsular polysaccharide, to the conjugates
incorporating this form and also to the methods of
production for obtaining it.
Pneumococcus (Streptococcus pneumoniae) is a Gram-
positive encapsulated bacterium responsible for
meningitis and bacteremia. It also causes a large
number of the respiratory infections such as
bronchitis, rhinitis or otitis with complications in
adults and in children. Pneumococci are divided into
serotypes according to the structure of the
polysaccharides which form the capsule. The serotyping
of pneumococci is carried out using a battery of immune
sera, each immune serum being specific for a single
type of capsular polysaccharide. More than 90 different
serotypes, all pathogenic to humans, have been
registered. Serotypes 6B, 14, 18C, 19F and 23F are
prevalent in young children and cause pneumonia and
otitis. Serotypes 1 and 5 are encountered more commonly
in developing countries than in industrialized
countries.
Vaccines which protect against the main serotypes
encountered clinically in humans have been developed or
are undergoing development. A vaccine comprising the
capsular polysaccharides of 23 different serotypes
responsible for 900 of pneumococcal infections (1, 2,
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,
17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) is effective in
adults and children over the age of two. On the other
hand, children under the age of two, due to the
immaturity of their immune system, do not respond to
this vaccine consisting of T-independent polysaccharide
antigens. This obstacle has been overcome by developing
CA 02512847 2005-07-08
- 2 -
vaccines containing capsular polysaccharides of various
pneumococcal serotypes coupled (conjugated) to one or
more carrier proteins (WO 98/51339). These conjugates
induce the development of a T-dependent protective
humoral immunity in young children, resulting in the
production of specific antibodies against the
polysaccharides of the various serotypes used in these
conjugates.
The capsular polysaccharides of the various serotypes
of pneumocaccus are all made up of a repeating base
unit (repeating unit) consisting of several sugars. By
way of illustration, it is indicated that the base unit
of the pneumococcus type 5 polysaccharide consists of 5
hexoses: glucose, N-acetylated fucosamine, N-acetylated
pneumosamine (2-acetamido-2,6-deoxytalose), glucuronic
acid and a sugar called Sug (2-acetamido
2,6-deoxyhexose-4-ulose) linked to one another to form
a chemical structure with the following condensed
formula:
4}-~i-D-Gicp-( 1-34}-a-L~FucpNAc-( 1 ~3)-~-D-Sugp-1-~
3
T
1
a-L-PnepNAc-(1 ~2}-(3-D-GlcAp
n
The expanded formula which corresponds thereto is
formula (I) as below:
C zOH ~H3
~,~.0
O GO O O= H3 0
H OH ~ _
OOH ~D ~ O~
HO O cxL -FucNAc ''
(3D-GtcA 0 GO
HO CH3
aL -PneNAc H
Ho H o
off Go
CH3
CA 02512847 2005-07-08
- 3 -
in which Sug signifies 2-acetamido-2,6-deoxyhexose-
4-ulose; PneNAc signifies 2-acetamido-2,6-deoxytalose,
also called N-acetylated pneumosamine; FucNAc signifies
2-acetamido-2,6-deoxygalactose, also called N-acety-
lated fucosamine; GIcA signifies glucuronic acid; and
Glc signifies glucose.
This formula was provided by P.E. Jannson et al.,
Carbohydrate Research (1985) 140 (1): 101. However, it
is not impossible for a small percentage of the
repeating units of the polysaccharide to have a
hydroxyl group in place of the ketone function.
Many methods exist for coupling a polysaccharide to a
carrier protein. Among these, methods which involve, in
a preliminary manner, reductive amination of the
polysaccharide are commonly used. For example, as
described in EP 562 107, the polysaccharide is first of
all coupled by reductive amination to a bifunctional
spacer of the NHz-R-NH2 type, and then the
polysaccharide thus derivatized and aminated is coupled
to a bifunctional linking agent in particular capable
of reacting with an amine function. The polysaccharide
thus activated is then conjugated to a carrier protein.
According to other variants, it is also possible to
couple the polysaccharide directly to the protein by
reductive amination, or even to omit the spacer.
As is well known, a reductive amination reaction takes
place in two steps. In a first step, an intermediate
compound, called Schiff base, of formula R-CH=NH+-R',
forms resulting from the interaction between an
aldehyde group of a first molecule (R-CHO) and a
primary amine group (R'-NH2) of a second molecule. The
Schiff base is then reduced in a second step in the
form of an amino compound R-CH2-NH-R' in the presence of
a reducing agent. Use is made of a selective reducing
CA 02512847 2005-07-08
- 4 -
agent capable of specifically reducing the imine
function of the Schiff base, such as a hydrogen
activated by catalyst, sodium cyanoborohydride (NaCNBH3)
or an amine borane. Cyanoborohydride or pyridine borane
is preferably used.
Since all the polysaccharides have an aldehyde function
at the end of the chain (terminal aldehyde function),
the conjugation methods comprising a reductive
amination of the polysaccharide can be applied very
generally and, when there is no other aldehyde function
in the repeating unit (intrachain aldehyde function),
such methods make it possible to obtain conjugates in
which a polysaccharide molecule is coupled to a single
molecule of carrier protein.
In an entirely conventional manner, a polysaccharide is
subjected to a reductive amination, in the presence of
a reducing agent selective for the Schiff base, for at
least 24 to 48 hours, at a neutral or basic pH.
Thus, US 4,761,283 describes the reductive amination of
the pneumococcus type 6A capsular polysaccharide
(prefragmented by acid hydrolysis) with a nontoxic
mutant of diphtheria toxin (mutant CRM 197), in the
presence of sodium cyanoborohydride. The pH of the
reaction medium is basic (pH - 8) and the incubation
period is 18 days at 37°C.
EP 477 508 describes the reductive amination of
pneumococcus type 6A, 14, 19F and 23F polysaccharides
with diaminomethane or diaminoethane, in the presence
of pyridine borane, which plays the role of reducing
agent for the Schiff base. The pH of the reaction
medium is 9.2. The reaction takes place for 48 hours.
CA 02512847 2005-07-08
- 5 -
In EP 562 107 mentioned above, the reductive amination
of the polysaccharide is carried out at pH 8 for 6
days.
Since the pneumococcus type 5 capsular polysaccharide
comprises an intrachain ketone function, it should
theoretically be expected that this ketone function, in
addition to the terminal aldehyde function, be amino-
reduced during the reductive amination of the
polysaccharide. Now, when the pneumococcus type 5
capsular polysaccharide and a capsular polysaccharide
of another serotype or of another species not
comprising any intrachain aldehyde and ketone functions
are subjected to the amination in parallel, the degrees
of amination are equivalent, which clearly appears to
confirm that only the terminal aldehyde function of the
pneumococcus type 5 capsular polysaccharide is aminated
and that only this function is modified during the
reaction. Now, in truth, this is not the case.
In fact, it is has now been discovered that the
chemical structure of the repeating unit of the
pneumococcus type 5 polysaccharide is modified after
reductive amination according to the conventional
method. This has been shown by nuclear magnetic
resonance (NMR) spectrometry and by high performance
anion-exchange chromatography coupled to pulsed
amperometric detection (HPAEC-PAD chromatography). The
vast majority of the Sug residue disappears in favor of
three new compounds: (i) N-acetylated ~i-D-quinovosamine
derived from reduction of the ketone function of the
Sug residue to an alcohol function and (ii) a compound
X resulting from a more considerable conversion of the
Sug residue . The third compound is none other than the
isomer of the N-acetylated (3-D-quinovosamine, i.e.
N-acetylated (3-D-fucosamine, also derived from
reduction of the Sug residue, and for which a slight
increase is observed.
CA 02512847 2005-07-08
- 6 -
In NMR spectrometry and as shown in Figure 1, the
pneumococcus type 5 polysaccharide in its simply
fragmented native form exhibits, in the resonance
region for the carbons of methyl groups at position 6
(C6) of sugars, the three resonance signals
characteristic of the methyl groups of N-acetylated
pneumosamine (PneNAc), of N-acetylated fucosamine
(FucNAc) and of the Sug residue (Fig. 1-spectrum 1).
The fragmentation does not in any way modify the
spectrum, but improves the resolution thereof. After
conventional amination with diaminohexane, in the
presence of sodium cyanoborohydride (NaCNBH3), it is
noted that the resonance signal characteristic of the
methyl group of the Sug residue (abbreviated to "signal
characteristic of the Sug residue") is substantially
decreased and this decrease is accompanied by the
appearance of two new resonance signals: one between 17
and 18 ppm, characteristic of N-acetylated
quinovosamine (QuiNAc) and the other between 13 and
14 ppm, which denotes a new compound, the structure of
which is unknown and which, for this reason, is named
compound X (Fig. 1-spectrum 4).
In HPAEC-PAD chromatography, when the chromatograms for
the products of hydrolysis with 2N trifluoroacetic
acid, for 2 hours at 120°C, of the native or
depolymerized polysaccharide and of the polysaccharide
obtained after conventional reductive amination are
compared, as shown in Figure 2 (the dot-dashed curve),
the appearance of a first peak (between 5.50 and
6.10 min when the chromatography is carried out under
the conditions specified later) corresponding to a
compound .derived from the reductive amination, the
structure of which is unidentified (compound X), and
also a second peak (between 6.90 and 7.40 min when the
chromatography is carried out under the conditions
specified later) characteristic of quinovosamine is
CA 02512847 2005-07-08
_ 7
noted. In addition, the intensity of the peak
corresponding to fucosamine is substantially increased.
It should be noted that the chromatograms, including
that of the native or depolymerized polysaccharide,
comprise no peak corresponding to the Sug residue.
Specifically, in order to be subjected to HPAEC-PAD
chromatography, the polysaccharide must first of all be
hydrolyzed. This hydrolysis destroys the Sug residue;
it also has the effect of converting QuiNAc, PneNAc and
FucNAc to quinovosamine (QuiN), pneumosamine (PneN) and
fucosamine (FucN).
In addition, it was discovered that conversion of the
Sug compound to compound X was harmful to the
immunogenicity of the polysaccharide, even though this
conversion is only partial - that is to say taking
place only in some of the repeating units of the
polysaccharide and not in all of them. On the other
hand, the QuiNAc or FucNAc conversion has no notable
influence.
It therefore appeared to be desirable to investigate
means which made it possible to avoid the appearance of
the compound X. This was made possible by modifying the
conventional procedure for reductive amination. In an
alternative manner, it is also possible to reduce the
ketone functions (C=0) of the native (nonfragmented)
polysaccharide beforehand. This can be carried out
using a strong reducing agent such as NaBH4. This
reducing agent does not generate any undesirable
compound. It reduces only the ketone and aldehyde
functions. However, since it reduces these functions,
it is then necessary to fragment the reduced
polysaccharide in order to reintroduce terminal
aldehyde groups. The reduction of the ketone functions
prevents any subsequent modification when the
polysaccharide is then subjected to any reductive
amination.
CA 02512847 2005-07-08
_ $
For this reason, a subject of the invention is:
(i) A pneumoeoccus type 5 capsular polysaccharide
which is aminated on the terminal aldehyde
group and which exhibits (i) a carbon (13C) NMR
spectrum lacking a resonance signal between 13
and 14 ppm inclusive; (ii) an HPAEC-PAD
chromatogram substantially lacking a peak
between the fucosamine and pneumosamine peaks,
the chromatogram being obtained by elution,
from a CarbopacTM PA10 column, in an 1$ mM
sodium hydroxide solution, at a flow rate of
1 ml/min for 15 min, of the monosaccharides
derived from the hydrolysis of said
polysaccharide; or (iii) both.
(ii) A conjugate in which the polysaccharide
according to the invention is coupled to a
carrier polypeptide (P).
(iii) A first method for producing an aminated
pneumococcus type 5 capsular polysaccharide,
according to which the polysaccharide is
subjected to a reductive amination in the
presence of a reducing agent selective for a
Schiff base, at a pH of 4 to 6.5, preferably of
5 to 6, for a period not exceeding 4 hours.
(iv) A second method for producing an aminated
pneumococcus type 5 capsular polysaccharide,
according to which (i) the polysaccharide is
reacted with an agent capable of reducing a
ketone function, (ii) the reduced
polysaccharide obtained in (i) is fragmented,
and (iii) the reduced and fragmented
polysaccharide is subjected to a reductive
amination.
CA 02512847 2005-07-08
- 9 -
In the remainder of the text, the term ~~aminated
polysaccharide" refers to a pneumococcus type 5
capsular polysaccharide which is aminated on the
terminal aldehyde group; that is to say derived from
the reaction of the terminal aldehyde function with an
amine function.
The reductive amination of a polysaccharide can be
carried out by reacting the terminal aldehyde function
of a polysaccharide with compounds which are very
diverse but of course all characterized in that they
have at least one primary amine function. These
compounds may be polypeptides or chemical compounds.
These polypeptides and these chemical compounds will be
mentioned in greater detail in the subsequent
description. When a polypeptide is involved, the
product of the reductive amination is in fact a
polysaccharide-polypeptide conjugate.
For use in the methods according to the invention, a
pneumococcus type 5 capsular polysaccharide is
advantageously pre-purified from a bacterial culture,
for example according to the method of Gotschlich et
al., J. Exp. Med. (1969) 129: 1349.
The polysaccharide may be used unmodified (reference is
then made to native form) or else fragmented. In fact,
the size of the polysaccharide is absolutely not
critical. In its native form, the polysaccharide
contains approximately 300 repeating units. A
fragmented polysaccharide may consist of at least 4
repeating units, in general from 25 to 100 repeating
units. If necessary, the size of a polysaccharide can
be determined according to known methods, for example
by determining its KD by gel filtration or by measuring
its molecular mass by SEC-triple detection (exclusion-
CA 02512847 2005-07-08
- 10 -
diffusion chromatography coupled with triple detection:
refractometry, viscosimetry, light scattering).
A polysaccharide can be fragmented according to various
methods known to those skilled in the art, for example
by controlled acid or basic hydrolysis or oxidative
free-radical depolymerization as described in
EP 562 107.
In the first method according to the invention, a
fragmented polysaccharide is preferably used; in the
second, a native polysaccharide.
In order to characterize the present invention, nuclear
magnetic resonance (NMR) spectrometry can be used
according to entirely conventional protocols; in
particular, the data can be collected using any type of
device intended for this purpose. Carbon NMR
spectrometry has already been widely used to study the
repeating units of a certain number of capsular
polysaccharides, in particular those of pneumococcus.
By way of example, mention is made of C. Jones et al . ,
Carbohyd. Res. (2000) 325: 292. Those skilled in the
art in the field of spectral analysis therefore have
sufficient information to carry out for themselves the
analysis of the type 5 polysaccharide by carbon NMR
spectrometry.
However, by way of example, a protocol for preparing
the samples is indicated, which is in particular
suitable for subsequent measurement in a Bruker DRX500
spectrophotometer with a broadband measuring probe
(spectral width: 27500 Hz). 12 to 17 mg of a
lyophilizate of a type 5 polysaccharide are dissolved
in 0.5 ml of heavy water (D20). This sample is placed in
a 5 mm tube specially designed for NMR analysis. The
spectra are then recorded at 70°C (343 K).
CA 02512847 2005-07-08
- 11 -
For the purposes of characterization, the HPAEC-PAD
chromatography should be carried out under very precise
conditions regarding the type of column, the elution
solutions and the elution flow rate. A complete
procedure is provided below.
The aminated polysaccharides should first of all be
hydrolyzed to monosaccharides. To do this, 5 to 20 ~,g
of aminated polysaccharide in solution in deionized
water at a concentration of 10-40 ~g/ml are treated
with 500 ~.l of 2N trifluoroacetic acid for 2 hours at
120°C in a hermetically stoppered flask. The
hydrolysates are dried under a stream of nitrogen at
40°C so as to remove the trifluoroacetic acid. The
residues are then dissolved in 400 ~.1 of deionized
water.
The chromatography is carried out on a CarboPacTM PA10
analytical column (4 x 250 mm) marketed by Dionex. This
column consists of a support based on polystyrene and
sulfonated divinylbenzene having a degree of cross-
linking of 55o covered with latex microbeads grafted
with quaternary ammonium groups. The degree of
crosslinking of the latex (latex microbeads) is 5%; the
diameter of the microbeads is 400 nm.
5 ~.g of hydrolysate are injected into the column. The
column is then subjected to a flow of an 18 mM sodium
hydroxide solution for 15 min at a flow rate of
1 ml/min, in order to elute the uncharged
monosaccharides and oligosaccharides such as hexoses
and hexosamines. To finish off the chromatogram, it is
possible to subsequently gradually increase the
molarity of the sodium hydroxide solution up to 100 mM
and, finally, to elute the remaining acidic
monosaccharides and oligosaccharides using a solution
of 100 mM sodium hydroxide/300 mM sodium acetate.
CA 02512847 2005-07-08
- 12 -
Throughout the entire elution, the flow rate is
1 ml/min and the temperature is 30°C.
Under these conditions, the distance between the
fucosamine and pneumosamine peaks is approximately
2 min. When the fucosamine and pneumosamine peaks
appear at 4.75 and 6.75 min respectively, the peak X,
if it should appear, appears between 5.50 and 6.10
(5.80 min).
The products obtained using each of the two methods
according to the invention both correspond to the
definition of the product according to the invention,
but differ with regard to the percentage of Sug
compound and of N-acetylated quinovosamine.
When the first method according to the invention (which
specifies optimized conditions for reductive amination)
is used, an aminated polysaccharide is obtained which
exhibits:
(i) a carbon NMR spectrum which comprises a
resonance signal between 11.5 and 12.5 ppm,
inclusive, characteristic of the Sug compound,
and a resonance signal located between 17 and
18 ppm inclusive, characteristic of
N-acetylated quinovosamine, the intensity of
which is less in comparison with the signal
located between 17 and 18 ppm, inclusive, in
the (I3C) NMR spectrum of a pneumococcus type 5
capsular polysaccharide obtained after
reductive amination, in the presence of sodium
cyanoborohydride, at pH 8, for 48 hours; or
(ii) an HPAEC-PAD chromatogram which comprises a
peak eluted immediately after the pneumosamine,
characteristic of quinovosamine, the intensity
of which is less in comparison with the
equivalent peak in the HPAEC-PAD chromatogram
CA 02512847 2005-07-08
- 13 -
of a pneumococcus type 5 capsular poly-
saccharide obtained after reductive amination,
in the presence of sodium cyanoborohydride, at
pH 8, for 48 hours; or
(iii) both.
It is not possible to quantify in absolute terms the
percentage of Sug residues which had been modified
after reductive amination, in a polysaccharide molecule
taken separately or in a set of molecules. On the other
hand, it is possible to indicate that the degree of
modification of the Sug residues is decreased by at
least 65% - when it is not by at least 70 or 75% - when
the pneumococcus type 5 capsular polysaccharide is
obtained in aminated form using the first method
according to the invention, in comparison with a
pneumococcus type 5 capsular polysaccharide aminated
according to a conventional method. After reductive
amination according to the first method according to
the invention, most of the modifications which persist
relate to the conversion of certain Sug residues of the
polysaccharide to N-acetylated quinovosamine: the
compound X is not substantially formed, as reflected by
the carbon NMR spectrum and the HPAEC-PAD chromatogram
(Figure 1 - 2nd spectrum and Figure 2 - dashed curve).
Specifically, the spectrum exhibits no resonance signal
between 13 and 14 ppm inclusive, characteristic of the
compound X, and the ,chromatogram simply exhibits a
broad peak of very low intensity between the fucosamine
and pneumosamine peak (between 5.50 and 6.10 min).
Using the first method according to the invention, it
is even possible to obtain an aminated polysaccharide
which exhibits (i) a carbon NMR spectrum definitely
lacking a resonance signal between 17 and 18 ppm; (ii)
an HPAEC-PAD chromatogram lacking a quinovosamine peak
(between 6.90 and 7.40 min), the peak observed with the
CA 02512847 2005-07-08
- 14 -
polysaccharide aminated according to a conventional
amination method being reduced so as to be no more than
a simple shoulder of the preceding peak (pneumosamine
peak); or (iii) both.
The second method according to the invention requires
the prior reduction of the ketone groups of the native
polysaccharide. Under these conditions, it is readily
understood that the Sug residues are essentially
converted to N-acetylated fucosamine and quinovosamine.
In that case, reference is made to a "reduced
polysaccharide". Reductive amination according to a
conventional procedure of the reduced and fragmented
polysaccharide has no notable effect on the structure
of the repeating units. This is clearly shown in
Figure 2 - curve with dashes and dots.
Thus, when the second method according to the invention
is used, an aminated polysaccharide is obtained which
exhibits:
(i) a carbon NMR spectrum lacking a resonance
signal between 11.5 and 12.5 ppm, inclusive,
characteristic of the Sug compound, which
comprises a resonance signal located between 17
and 18 ppm inclusive, characteristic of
N-acetylated quinovosamine, the intensity of
which is increased in comparison with the
resonance signal located between 17 and 18 ppm,
inclusive, in the (13C) NMR spectrum of a
pneumococcus type 5 capsular polysaccharide
obtained after reductive amination, in the
presence of sodium cyanoborohydride, at pH 8,
for 48 hours; or
(ii) an HPAEC-PAD chromatogram which comprises a
peak located immediately after the pneumosamine
peak, characteristic of quinovosamine, the
intensity of which is increased in comparison
CA 02512847 2005-07-08
- 15 -
with the equivalent peak in the HPAEC-PAD
chromatogram of a pneumococcus type 5 capsular
polysaccharide obtained after reductive
amination, in the presence of sodium
cyanoborohydride, at pH 8, for 48 hours; or
(iii) both:
In~other words, an aminated polysaccharide according to
the invention, aminated on the terminal aldehyde group,
essentially consists of repeating units of formula (II)
O C i0H O
~H3
rte
j3D-Glc 0 A H3 0
H OH 0 /
HO ~_OOH G aL-FucNa~ ~ 0
GO
HO aD-GIcA O
CH,
aL-PneNAc 0 H
HO
off o (II)
cH'
in which A is independently and randomly C=0 or CHOH.
The expression "aminated polysaccharide essentially
consisting" is intended to mean a polysaccharide
aminated on the terminal aldehyde group in which the
percentage of repeating units of formula (II) is at
least 85%, preferably at least 90%, entirely preferably
at least 950.
Depending on the method used to produce the aminated
polysaccharides according to the invention, the
proportion of repeating units of formula (II) in which
A is C=O (formula (TI')) can vary considerably and,
consequently, the same goes for the proportion of
repeating units of formula (II) in which A is CHOH
(formula (II")).
CA 02512847 2005-07-08
- 16 -
The second method according to the invention generates
an aminated polysaccharide in which the repeating units
correspond to formula (II") since, in NMR, the
resonance signal corresponding to the Sug residue
disappears in favor of the resonance signal
corresponding to N-acetylated quinovosamine. The
polysaccharide contains at least 950 of repeating units
of formula (II").
On the other hand, using the first method according to
the invention, an aminated polysaccharide is produced
in which the units of formula (II')/units of formula
(II") ratio is clearly different. Specifically, in NMR,
the resonance signal corresponding to the Sug residue
is visible, as is that corresponding to the
N-acetylated quinovosamine. The polysaccharide contains
from 85 to 950 of repeating units of formula (II').
As pointed out previously, a polysaccharide according
to the invention can be aminated using various
compounds. When the polysaccharide according to the
invention is intended for the production of conjugates,
the compound for aminating the polysaccharide is
advantageously chosen according to the structure that
it is hoped these conjugates will be given. In general,
the conjugates according to the present invention
correspond to the formula Ps-CHZ-NH-R in which:
Ps denotes the pneumococcus type 5 capsular
polysaccharide essentially consisting of repeating
units of formula (II);
R is a carrier polypeptide P;
a compound of formula (IIT) L-P, in which a
carrier polypeptide is linked to a linking
agent (L); or
a compound of formula (III') S-L'-P, in which a
carrier polypeptide P is linked to a spacer (S)
via a linking agent (L');
CA 02512847 2005-07-08
' - 1~ -
C denotes the carbon atom of the terminal aldehyde
group of the polysaccharide; and
N denotes the nitrogen atom of the amine group provided
by R.
The compounds P, L and S will be described later in the
description, in the section devoted to the conjugates.
It is, however, noted from hereon that these compounds
must all of course comprise a free primary amine group
capable of reacting with an aldehyde function. They may
be used in each of the two methods according to the
in~rention, without any distinction.
In the first method according to the invention, the
reductive amination to which the polysaccharide is
subjected consists in particular in reacting the
polysaccharide with a compound comprising an amine
function such as the compounds P, L or S, in the
presence of a reducing agent selective for a Schiff
base, such as cyanoborohydride or pyridine borane,
under the conditions of pH and of temperature already
specified, preferably between 30 min and 4 hours.
In order to obtain a degree of amination similar to
that obtained under conventional conditions, an
incubation time of between 2 and 4 hours, inclusive, is
recommended. When the incubation time does not exceed 2
hours, the Sug compounds are not modified. Beyond 2
hours, reduced Sugs are observed in the form of N-
acetylated f~-D-quinovosamine and/or N-acetylated fi-D
fucosamine, generally coexisting with unmodified Sugs
in the polysaccharide chain. Consequently, the longer
the incubation time, the greater the proportion of
reduced Sug. Beyond 4 hours, the undesirable compound X
is identified by NMR.
So as not to prolong the reductive amination reaction
time beyond the required time, this reaction should be
CA 02512847 2005-07-08
- 18 -
stopped by rapid methods, in particular by selective
precipitation of the aminated polysaccharide. The
aminated polysaccharide is, for example, purified by
alcoholic precipitation when the aminated compound is a
linking agent or a spacer. Precipitation with ammonium
sulfate is preferred when the aminated compound is a
polypeptide. The methods of purification by precipita-
tion are conventional methods, well known to those
skilled in the art.
The reductive amination generally takes place in a
buffered medium such as the citrate/phosphate buffer is
used, but another buffer with a pKa of between 2.5 and
6 is also suitable. By way of example, a citrate,
acetate or succinate buffer may be used. Buffers for
which the chemical formula comprises compounds carrying
an amino group, such as, for example, a glycine buffer
are, however, excluded.
The temperature of the reaction medium is generally
between 4 and 70°C, depending on the aminated compound
used, preferably between 20 and 50°C, and even more
preferably between 20 and 37°C, when the aminated
compound is a polypeptide.
For use in the first method according to the invention,
the polysaccharide may be either native or fragmented
beforehand. Any method of fragmentation may be
suitable, on condition that it preserves the structural
integrity of the native polysaccharide. The free-
radical fragmentation method described later is most
particularly suitable.
Although the weight ratios between the polysaccharide,
the aminated compound and the cyanoborohydride are not
critical, better yields of aminated polysaccharides are
obtained in the range of polysaccharide/aminated
compound/cyanoborohydride weight ratios ranging from
CA 02512847 2005-07-08
- 19 -
1/0.1/0.02 to 1/510.2 when a linking agent L or a
spacer S is used as aminated compound; or in the range
of weight ratios ranging from 1/0.2/0.02 to 1/1/0.2
when a carrier polypeptide is used as aminated
compound. The optimum yields of aminated
polysaccharides are obtained with a 1/1/0.1 ratio when
the aminated compound is a linking agent or spacer or
with a 1/0.5/0.1 ratio when the aminated compound is a
carrier polypeptide.
For use in the second method according to the
invention, the polysaccharide is preferably a native,
nondepolymerized polysaccharide, since, for carrying
out this second method, the polysaccharide is
necessarily subjected to fragmentation, after
reduction, so as to reintroduce terminal aldehyde
groups.
In the second method according to the invention, the
reduction of the polysaccharide is carried out
conventionally, e.g. at ambient temperature, in aqueous
medium, at basic pH, preferably at a pH of between 8
and 10. The strong reducing agent specific for the
ketone and aldehyde functions is used in excess, e.g.
at a molar concentration of at least 10 times,
preferably of at least 100 times, greater than that of
the polysaccharide. A borohydride, such as sodium
borohydride (NaBH4), is a reducing agent of choice. The
reaction time may be 30 min to 2 hours, preferably 1
hour. The reduced polysaccharide can then be purified
by any method, preferably by alcoholic precipitation.
The depolymerization of the reduced polysaccharide can
be carried out in particular by controlled hydrolysis.
The oxidative free-radical depolymerization method as
described in EP 562 107 is preferably used. The
fragmented polysaccharides can then be purified
conventionally, e.g. by alcoholic precipitation before
the reductive amination step.
CA 02512847 2005-07-08
- 20 -
In the second method according to the invention, the
reductive amination can be carried ou.t under any
conditions, including conventional conditions, since
there is no longer any Sug compound in the structure of
the reduced and fragmented polysaccharide and,
consequently, no longer any risk of forming the
undesirable compound X.
Thus, in the second method according to the invention,
the reductive amination to which the polysaccharide is
subjected simply requires reaction of the
polysaccharide with a compound comprising an amine
function, such as the compounds P, Z or S, in the
presence of a reducing agent selective for a Schiff
base.
It is possible to use the conditions described for the
first method according to the invention and, since, in
this case, the incubation time and also the pH are no
longer critical, with or without the time limitations
or the restrictions relating to the pH range.
Generally, under conventional conditions, the pH of the
reaction medium is within a broad range of from 5 to 9,
but a pH of between 5 and 8 is preferably chosen. An
incubation time generally of between 2 hours and 48
hours gives good yields of aminated polysaccharide. The
incubation temperature is generally between 20°C and
50°C.
Once the reductive amination has been carried through
to a successful conclusion, the aminated polysaccharide
is purified from the reaction medium by means of usual
methods, e.g. by alcoholic or ammonium sulfate
precipitation, by dialysis, by exclusion-diffusion
chromatography or by ultrafiltration, according to
needs.
CA 02512847 2005-07-08
- 21 -
As previously mentioned, an aminated polysaccharide may
already be a conjugate when the compound having reacted
with the terminal ~ aldehyde function of the
polysaccharide is a carrier polypeptide. This conjugate
has the formula Ps-CH2-NH-P, in which the polysaccharide
(Ps) is directly coupled to the carrier polypeptide
(P) .
For this reason, the subject of the invention is also:
to
a. A method for producing a conjugate according to
the invention of formula (IV) Ps-CH2-NH-P in which
Ps denotes the pneumococcus type 5 capsular
polysaccharide; according to which method the
polysaccharide is reacted with a carrier
polypeptide (P), in the presence of a reducing
agent selective for a Schiff base, at a pH of 4 to
6.5, preferably of 5 to 6, for a period not
exceeding 4 hours.
b. A method for producing a conjugate according to
the invention of formula (IV) Ps-CHZ-NH-P in which
Ps denotes the pneumococcus type 5 capsular poly-
saccharide; according to which method (i) the
native polysaccharide is reduced with a strong
reducing agent specific for ketone and aldehyde
functions, (ii) the reduced polysaccharide is
fragmented, and (iii) the reduced and fragmented
polysaccharide is subjected to a reductive amina-
tion in the presence of a carrier polypeptide P.
c. A method for producing a conjugate according to
the invention of formula (V) Ps-CHZ-NH-L-P,
according to which:
(i) a pneumococcus type 5 capsular polysaccharide
(Ps) is reacted with a linking agent (L)
having at least one primary amine function,
in the presence of a reducing agent selective
CA 02512847 2005-07-08
- 22 -
for a Schiff~base, at a pH of 4 to 6.5,
preferably of 5 to 6, for a period not
exceeding 4 hours, in order to obtain an
activated polysaccharide of formula (VI) Ps
CHZ-NH-L, and
(ii) the activated polysaccharide is coupled to a
carrier polypeptide (P) in order to obtain
the conjugate of formula (V) Ps-CHZ-NH-L-P; or
alternatively,
d. A method for producing a conjugate according to
the invention of formula (V) Ps-CHZ-NH-L-P,
according to which a pneumococcus type 5 capsular
polysaccharide (Ps) is reacted with an activated
carrier polypeptide of formula (VIT) L-P, in which
L is a linking agent having at least one primary
amine function and P is a carrier polypeptide, in
the presence of a reducing agent selective for a
Schiff base, at a pH of 4 to 6.5, preferably of 5
to 6, for a period not exceeding 4 hours, in order
to obtain the conjugate of formula (V) Ps-CH2-NH-L-
P.
e. A method for producing a conjugate according to
the invention of formula (V) Ps-CH2-NH-L-P,
accor ding to which:
(i) a pneumococcus type 5 capsular poly-
saccharide (Ps) is reacted with an agent
capable of reducing a ketone
function,
(ii) the reduced polysaccharide
is fragmented,
(iii) the reduced and fragmented polysaccharide
is coupled, by reductive am ination, with
a
linking agent (L) having at least one
primary amine function, in order to obtain
an activated polysaccharide of formula (VI)
Ps-CH2-NH-L, and
the activated polysaccharide is coupled to a
carri er polypeptide (P), in order to obtain the
CA 02512847 2005-07-08
- 23 -
conjugate of formula (V) Ps-CH2-NH-L-P, or
alternatively,
f. A method for producing a- conjugate according to
the invention of formula (V) Ps-CH2-NH-L-P,
according to
which:
(i) a pneumococcus type 5 capsular poly-
saccharide (Ps) is reacted with an agent
capable of reducing a ketone function,
(ii) the reduced polysaccharide is fragmented,
and
(iii) the reduced and fragmented polysaccharide
is coupled, by reductive amination, with an
activated carrier polypeptide of formula
(VII) L-P, in which L is a linking agent
having at least one primary amine function,
in order to obtain the conjugate of formula
(V ) Ps-CH2-NH-L-P .
g. A method for producing a conjugate according to
the invention of formula (VIII) Ps-CH2-NH-S-L'-P,
according to which:
(i) a pneumococcus type 5 capsular poly
saccharide is reacted with a spacer (S)
having at least one primary amine function,
in the presence of a reducing agent
selective for a Schiff base, at a pH of 4
to 6.5, preferably of 5 to 6, for a period
not exceeding 4 hours, in order to obtain a
derivatized polysaccharide of formula (IX)
Ps-CHZ-NH-S,
(ii) the derivatized polysaccharide is coupled
with a linking agent (L'), in order to
obtain an activated polysaccharide of
formula (X) Ps-CH2-NH-S-L' , and
(iii) the activated polysaccharide is coupled
with a carrier polypeptide (P), in order to
CA 02512847 2005-07-08
- 24 -
obtain the conjugate of formula (VIII)
Ps-CH2-NH-S-L' -P; or alternatively,
h. A method for producing a conjugate according to
the invention of formula (VIII) Ps-CHZ-NH-S-L'-P,
according to which:
(i) a pneumococcus type 5 capsular poly-
saccharide is reacted with a spacer (S)
having at least one amine function, in the
presence of a reducing agent selective for
a Schiff base, at a pH of 4 to 6.5,
preferably of 5 to 6, for a period not
exceeding 4 hours, in order to obtain a
derivatized polysaccharide of formula (IX)
Ps-CHZ-NH-S, and
(ii) the derivatized polysaccharide is coupled
with an activated carrier polypeptide of
formula (XI) L'-P, in which L' is a linking
agent and P is a carrier polypeptide, in
order to obtain the conjugate of formula
(VIII) Ps-CHZ-NH-S-L' -P.
i. A method for producing a conjugate according to
the invention of formula (VIII) Ps-CH2-NH-S-L'-P,
according to which:
(i) a pneumococcus type 5 capsular poly-
saccharide (Ps) is reacted with an agent
capable of reducing a ketone function,
(ii) the reduced polysaccharide is fragmented,
(iii) the reduced and fragmented polysaccharide
is coupled, by reductive amination, to a
spacer (S) carrying at least one primary
amine function, in order to obtain a
derivatized polysaccharide of formula (IX)
Ps-CH2-NH-S,
(iv) the derivatized polysaccharide is coupled
to a linking agent (L'), in order to obtain
CA 02512847 2005-07-08
- 25 -
an activated polysaccharide of formula (X)
Ps-CH2-NH-S-L' , and
(v) the activated polysaccharide is coupled to
a carrier polypeptide (P), in order to
obtain the conjugate of formula (VIII)
Ps-CH2-NH-S-L' -P; or alternatively,
j. A method for producing a conjugate according to
the invention of formula (VIII) Ps-CH2-NH-S-L'-P,
according
to which:
(i) a pneumococcus type 5 capsular polysaccha-
ride (Ps) is reacted with an agent capable
of reducing a ketone function,
(ii) the reduced polysaccharide is fragmented,
(iii) the reduced and fragmented polysaccharide
is coupled, by reductive amination, to a
spacer (S) carrying at least one primary
amine function, in order to obtain a
derivatized polysaccharide of formula (IX)
Ps-CH2-NH-S, and
(iv) the derivatized polysaccharide is coupled
with an activated carrier polypeptide of
formula (XI) L'-P, in which L' is a linking
agent and P is a carrier polypeptide, in
order to obtain the conjugate of formula
(VIII) Ps-CH2-NH-S-L'-P.
In its most general scope, the term "carrier
polypeptide (P)" denotes a chain of amino acids,
whatever its size, and the post-translational
modifications which could have occurred, comprising at
least one "T-helper" epitope. Since it is known that a
T-helper epitope can consist of 10-15 amino acids, the
term "carrier polypeptide" encompasses peptides. Of
course, it also encompasses proteins.
The term "T-helper epitope" is intended to mean a chain
of amino acids which, in the context of one or more MHC
CA 02512847 2005-07-08
- 26 -
molecules, activates T-helper lymphocytes. The carrier
polypeptide of the conjugate causes the development of
T-dependent immunity specific for the pneumococcus type
polysaccharide, with production of specific anti-
s bodies against the polysaccharide, subsequent to the
administration of the conjugate. It also induces an
increase in the specific antibody titer at the time of
a booster immunization.
For use in the conjugates according to the invention,
the carrier polypeptide may be a bacterial toxoid
obtained by chemical detoxification, such as tetanus
toxoid, or obtained by genetic mutation, such as
diphtheria toxoid (CRM I97, by way of example),
Pseudomonas aeruginosa exoprotein A or Staphylococcus
aureus exotoxin A. It is also~possible to use the outer
membrane proteins of bacteria, such as the OMP1 or OMP2
proteins of Neisseria meningitides; the lambB, OmpC,
OmpaA, OmpF and PhoE proteins of Eseherichia col.i, the
CotC or CotD protein of Bacillus su.btilis, bacterial
porins such as Neisseria meningitides B Class 1 porin
or K.iebsiella pneumon.zae porin P40; also lipoproteins
such as Borelia burgdorfi OspA, Streptococcus
pneumoniae PspA, Nezsseria meningitides Transferrin
binding protein type 2 (TBP2), Escherichia coli TraT,
Streptococcus pneumoniae adhesin A. Proteins of viral
origin, such as influenza virus hemagglutinin can also
play the role of carrier polypeptide, as can the p24E,
p24N, p24M and p24H peptides described in WO 94/29339,
carrying a T-helper epitope, or the PADRE (PanDR T-
helper epitope) peptides described by Del guercio et
al. (Vaccine (1997), Vol. 15/4, p. 441-448).
The production of the conjugates of formula (IV) Ps-CH2-
NH-P is carried out in a single step, the reaction of
reductive amination of the polysaccharide also
providing the conjugation of the polysaccharide to the
polypeptide. On the other hand, the production of the
CA 02512847 2005-07-08
- 27 -
conjugates of formula (V) Ps-CHZ-NH-L-P or (VIII)
Ps-CH2-NH-S-L-P is carried out in several different
steps, the first step consisting of the implementation
of one of the two methods for producing an aminated
polysaccharide according to the invention, resulting in
the reductive amination of the polysaccharide with the
compound L or S.
The spacer S and the linking agents L and L' are
compounds having at least two functional groups
arranged within the compound in relatively opposite
directions. As regards the spacer S and the linking
agent L, one of the functional groups should be capable
of reacting with the terminal aldehyde of the
polysaccharide during the reductive amination, the
other being respectively capable of reacting with a
linking agent L' or with a carrier polypeptide. As
regards the linking agent L', one of the functional
groups should be capable of reacting with the spacer,
the other being capable of reacting with a carrier
polypeptide.
For the purposes of the present invention, the linking
agent L is a compound of the formula (XII) R1-A-R2, in
which:
A denotes an aliphatic or aromatic chain, or a mixed
aliphatic and aromatic chain which may be substituted
or.unsubstituted, saturated or unsaturated;
R1 denotes a primary amine or a chemical radical
carrying a primary amine, such as, for example, the
radical hydrazide, NH2-NH-CO; and
R2 denotes a functional group capable of reacting with
a functional group of the carrier polypeptide.
Advantageously, A denotes an alkyl, an alkylene or a
dithioalkyl, comprising from 1 to 12, advantageously
from 2 to 8, preferably from 2 to 6, carbon atoms.
CA 02512847 2005-07-08
- 28 -
Advantageously, R2 is capable of reacting with a
carboxyl, thiol or amine group. Thus, R2 can be,
independently of Rl, an amine group or a radical
carrying an amine group, such as the radical hydrazide.
R2 can also be a thiol or carboxyl group.
Thus, a compound of formula R1-A-R2 can be an alkyl
dihydrazide such as adipic acid dihydrazide; a
monoamino thioalkyl such as cysteine or cysteamine, or
a diamino thioalkyl such as cystamine; a diaminoalkyl
or diaminoalkylene, such as diaminomethane,
diaminoethane or diaminohexane.
For the purposes of the present invention, the spacer S
is a compound of formula (XIII) R1-A-R2', in which:
A denotes an aliphatic and/or aromatic chain which may
be substituted or unsubstituted, saturated or unsatu-
rated;
Rl denotes a primary amine or a chemical radical
carrying a primary amine, such as, for example, the
radical hydrazide, NHZ-NH-C0; and
R2' denotes a functional group capable of reacting with
a functional group of a linking agent L'.
According to a particular mode, the spacer S can be
chosen from the compounds of formula (XII) R1-A-R2.
For the purposes of the present invention, the choice
of the linking agent L' is conditioned firstly by the
functional group R2' carried by S, then by the
functional group of the carrier polypeptide which must
intervene in the conjugation operation. The linking
agent L' is a compound of formula (XIV) R3-B-R4, in
which:
B denotes an aliphatic and/or aromatic chain which may
be substituted or unsubstituted, saturated or unsatu-
rated;
CA 02512847 2005-07-08
- 29 -
R3 denotes a functional group capable of reacting with
the functional group R2'; and
R4 denotes a functional group capable of reacting with
a functional group of the carrier polypeptide.
Advantageously, B denotes an alkyl or an alkylene which
may be substituted or unsubstituted, comprising from 1
to 12, preferably from 2 to 8, carbon atoms; an aryl,
an alkylaryl or an arylalkylene, comprising from 7 to
12 carbon atoms; a phenyl or phenylene which may be
substituted or unsubstituted.
When R2' is a thiol group, R3 can be a thiol group; an
unsaturated a- or (3-carbonyl or an imidyl group, in
particular a maleimidyl group; an acyl halide or an
alkyl halide, in which the halogen is a bromine, a
chlorine or an iodine.
Advantageously, R4 is capable of reacting with a
carboxyl, thiol or amine group. Thus, if the functional
group of the carrier polypeptide which must intervene
in the conjugation operation is a thiol, R4 can be a
maleimide group. Similarly, if the functional gxoup of
the carrier polypeptide which must intervene in the
conjugation operation is an amine, R4 can be a carboxyl
group or preferably an N-hydroxysuccinimidyl or
N-hydroxysulfosuccinimidyl group.
When the spacer S is an aminothiol such as cysteine,
cysteamine or cystamine, the linking agent L' is
advantageously a succinimidyl maleimidyl alkyl. The
latter may in particular be y-maleimidobutyric acid
N-hydroxysuccinimide ester or N-sulfosuccinimide ester
(GMBS or sulfo-GMBS), E-maleimidocaproic acid
N-hydroxysuccinimide ester (MCS), succinimidyl
4-(p-maleimidophenyl) butyrate (SMPB) or sulfo-
succinimidyl 4-(p--maleimidophenyl) butyrate (sulfo-
SMPB), maleimidobenzoic acid N-hydroxysuccinimide ester
CA 02512847 2005-07-08
- 30 -
(MBS) or maleimidobenzoic acid N-hydroxysulfo-
succinimide ester (sulfo-MBS), 4-(N-maleimidomethyl)-
cyclohexanecarboxylic acid N-hydroxysuccinimide ester
(SMCC) or 4-(N-maleimidomethyl)cyclohexanecarboxylic
acid N-hydroxysulfosuccinimide ester (sulfo-SMCC).
When the spacer S is a diaminoalkyl or a dihydrazide,
the linking agent L' is advantageously chosen from the
disuccinimidylalkyl or succinirnidylmaleimidoalkyl
compounds of formula (XIV) R3-B-R4 in which B is an
alkyl group, R3 is a succinimidyl group and R4 is a
succinimidyl or maleimido group.
The disuccinimidyl group can be disuccinimidyl suberate
(DSS), bis(sulfosuccinimidyl) suberate (BS3),
disuccinimidyl glutarate (DSG), the succinimidyl
diester of adipic acid (SIDEA) or the succinimidyl
diester of succinic acid. The succinimidyl and or
sulfosuccinimidyl groups are capable of reacting with
an amine group. The succinimidylmaleimidoalkyl compound
can be one of those mentioned above.
In the methods of conjugation a. to j., the steps of
derivatization, of activation and of conjugation per se
can be carried out according to procedures well known
to those skilled in the art. They are in particular
described in the reference work entitled Bioconjugate
Techniques (1996) Ed Academic press. By way of example,
reference is made to this work to indicate that
conjugation reactions using an amine group and a
carboxyl group are advantageously carried out in the
presence of a carbodiimide.
The steps of derivatization, of activation and of
conjugation have no effect on the chemical structure of
the repeating units of the polysaccharide.
CA 02512847 2005-07-08
- 31 -
The conjugates obtained according to one of the methods
a. to j. can be finally purified, e.g. by ammonium
sulfate precipitation, by ultrafiltration, by
exclusion-diffusion chromatography or by partition
chromatography, in order to remove the residual,
unconjugated polysaccharide and protein fractions.
The subject of the invention is also a pharmaceutical
composition for therapeutic or prophylactic use,
comprising a polysaccharide according to the invention,
preferably in the form of a conjugate. The latter can
be formulated with a pharmaceutically acceptable
diluent or support, e.g. a phosphate buffer, and, where
appropriate, a lyophilization excipient. In general,
these products can be selected as a function of the
method and the route of administration and according to
the standard pharmaceutical practices. The suitable
diluents, and also that which is essential in
developing a pharmaceutical composition, are described
in Remington's Pharmaceutical Sciences, which serves as
a standard reference in this field. The composition can
also contain an adjuvant, e.g. an aluminum hydroxide,
an aluminum phosphate or an aluminum hydroxyphosphate.
A preserving agent such as phenoxyethanol formol can
2S also be used. An immunization dose can be prepared in a
volume of 0.1 ml to 2 ml, preferably in a volume of
0.5 ml. By way of example, it is indicated that a dose
can contain 0.475 mg of P0~2- ion, 4.5 mg of sodium
chloride and optionally 300 ~g of AL3+ ions. The
immunization composition according to the invention may
also be combined with other immunization antigens, in
particular pneumococcus polysaccharide antigens, which
may or may not be conjugated to a polypeptide carrier.
A multivalent vaccine against pneumococcus is then
obtained, in which the pneumococcus type 5
polysaccharide is in one of the forms described in the
invention.
CA 02512847 2005-07-08
- 32 -
A subject of the invention is also a method of
treatment or prevention against the pneumococcus type 5
infections, which consists in administering, to
infants, young children,, adults or elderly individuals,
a sufficient dose of a composition according to the
invention, optionally adjuvanted, so as to induce a
protective specific immune response against this
pathogen. The method is carried out by administration
of at least one immunization dose of the composition
according to the invention. For example, between 1 and
3 injections may be given, but preferably 3 injections
are given, leaving a period of one month between each
injection. A composition according to the invention may
be administered by any conventional route of use in the
vaccine field, in particular systemically, i.e.
parenterally, e.g. subcutaneously, intramuscularly,
intradermally or intravenously; or mucosally, e.g.
orally or nasally. The amount administered takes into
account the carrier polypeptide used for the route of
administration. By way of example, the dose of
polysaccharide required contained in the conjugate in
order to observe protective immunity against serotype 5
subsequent to parenteral administration is generally
between 0.5 ~g and 20 ~Cg, but preferentially between
0.5 and 5 ~,g, and even more preferably between 0.5 ~.g
and 2 ~,g, when the carrier protein is the tetanus
toxoid. In an unconjugated form, the dose of
polysaccharide required is between 10 and 50 ~,g,
preferably between 20 and 30 fig.
The present invention will be more clearly understood
in light of the following examples which serve to
illustrate the invention without, however, limiting the
contents thereof.
Figure 1 represents the NMR spectra of a polysaccharide
aminated according to various methods of production.
CA 02512847 2005-07-08
- 33 -
The first spectrum is that of the fragmented
pneumococcus type 5 polysaccharide after oxidative
free-radical depolymerization. In the region of the
high fields of the spectrum, the resonance signals of
the methyl carbons of the 3 N-acetylated hexosamines of
the repeating unit of the polysaccharide: N-acetylated
fucosamine (C6 FucNAc), N-acetylated pneumosamine (C6
pneNAc) and Sug (C6 Sug), are identified.
The second spectrum is that of the aminated
polysaccharide obtained according to the second method
which is the subject of the invention. The
disappearance of the signal corresponding to Sug (C6
Sug) and the appearance of a new signal corresponding
to N-acetylated quinovosamine (C6 QuiNAc), are
observed.
The third spectrum is that of the aminated
polysaccharide obtained according to the first method
which is the subject of the invention. It is identical
to the NMR spectrum of the fragmented, nonaminated
polysaccharide.
The fourth spectrum is that of the polysaccharide
aminated under conventional conditions. The presence of
two additional signals in the region of the high fields
of the spectrum is noted, corresponding to N-acetylated
quinovosamine and to the compound X and also a decrease
in the height of the signal corresponding to Sug.
Figure 2 represents the chromatogram obtained by HPAEC-
PAD of the depolymerized native polysaccharide (curve
with continuous line), of the polysaccharide aminated
according to the conventional method of reductive
amination (the en-dashed curve), according to the first
method which is the subject of the invention (dashed
curve) or according to the second method which is the
subject of the invention (curve with dashes and dots).
CA 02512847 2005-07-08
- 34 -
Example l: Reductive amination at pH 6, for 2 hours,
of the pneumococcus type 5 capsular
polysaccharide, after fragmentation
a) Free-radical depolymerization of the native
pneumococcus type 5 polysaccharide
The polysaccharide at a concentration of 2.5 mg/ml in
aqueous solution is fragmented with ascorbic acid,
ferrous sulfate and also cupric sulfate. The number-
amount of mmol of ascorbic acid is one hundred times
greater than that of the ferrous sulfate and of the
cupric sulfate. The weight ratio of ascorbic acid to
the polysaccharide is 0.1. The reaction mixture is
incubated in a water bath at 30°C in the dark for 1
hour 30 min. The hydrolyzed polysaccharide is purified
by precipitation in 80% ethanol, followed by
centrifugation. The centrifugation pellet is dialyzed
and then lyophilized. The average size of the
fragmented polysaccharide is approximately 30-35
repeating units, as measured by exclusion
chromatography with triple detection (Viscoteck).
b) Reductive amination of the polysaccharide
The fragmented polysaccharide is redissolved in a
citrate/phosphate, 0.2 M buffer, pH 6, at a
concentration of 10 mg/ml in the presence of
diaminohexane (DAH) hydrochloride (Aldrich) and sodium
cyanoborohydride (NaCNBH3) (Sigma). The
polysaccharide/DAH hydrochloride and NaCNBH3/DAH hydro-
chloride weight ratios are, respectively, 0.8 and 0.1.
The reaction mixture is incubated at 50°C in a water
bath for 2 hours. The reaction is then stopped by
precipitation of the aminated polysaccharide in 800
ethanol, followed by centrifugation. The precipitation
pellet is then taken with 0.5 M NaCI, in a proportion
CA 02512847 2005-07-08
- 35 -
of 10 mg/ml of polysaccharide, and then subjected to 8
successive dialysis baths (first 4 baths carried out in
a 0.5 M NaCl solution, followed by 4 baths carried out
in ultrafiltered water). The derivatized and thus
aminated polysaccharide is finally lyophilized.
Example 2: Reductive amination of the pneumococcus
type 5 capsular polysaccharide, after
reduction and fragmentation
a) Reduction and fragmentation of the native
polysaccharide
10 mg of sodium borohydride (NaBH4), are added to 10 ml
of an aqueous solution of native polysaccharide at
10 mg/ml, adjusted to pH 9 ~ 0.5 with 1 N aqueous
ammonia, and then the reaction mixture is left at
ambient temperature for 2 hours in the dark. The NaBH4
is then destroyed by adding a few drops of glacial
acetic acid. The reduced polysaccharide is subsequently
dialyzed against water, and is then fragmented using
the protocol described in paragraph a) in Example 1. A
polysaccharide containing on average 30-35 repeating
units is obtained. The reduced and fragmented
polysaccharide is subsequently lyophilized.
b) Reductive amination of the reduced and fragmented
polysaccharide
The reduced and fragmented polysaccharide is
redissolved in a 0.2 M phosphate buffer, pH 7.5, at a
concentration of 10 mg/ml in the presence of
diaminohexane (DAH) hydrochloride and sodium cyanoboro-
hydride (NaCNBH3) prepared extemporaneously. The
polysaccharide/DAH hydrochloride and NaCNBH3/DAH hydro-
chloride weight ratios are, respectively, 0.8 and 0.1.
The reaction mixture is incubated at 50°C in a water
bath for 48 to 72 hours. The aminated polysaccharide is
CA 02512847 2005-07-08
- 36 -
then purified by precipitation in 80o ethanol, followed
by centrifugation. The precipitation pellet is taken up
with 0.5 M NaCl, in a proportion of 10 mg/ml of
polysaccharide, and then subjected to 8 successive
dialysis baths (first 4 baths carried out in a 0.5 M
NaCl solution, followed by 4 baths carried out in
ultrafiltered water). The derivatized and thus aminated
polysaccharide is finally lyophilized.
Example 3: Production and study of the immunogenic
capacity of the conjugates obtained using
the derivatized and aminated poly-
saccharides of Examples 1 and 2.
a) Production of the conjugates
The aminated polysaccharides of Examples 1 and 2 are
conjugated to tetanus toxoid (TT) via DSS. Initially,
the aminated polysaccharide is activated with DSS, and
then the tetanus toxoid is conjugated to the activated
polysaccharide.
The aminated polysaccharide of Example 1 or 2 is taken
up in aqueous solution at a concentration of 40 mg/ml.
The DSS is taken up in a solution of DMSO in a
proportion of 5 mg/ml. 2.5 ml of an aqueous solution of
the aminated polysaccharide are added, dropwise, to
10 ml of the solution of DSS, with stirring. After
incubation for 1 h 30, the reaction is stopped by
precipitation in 50 ml of acetone. The precipitate is
recovered by filtration over a biichner No. 5, which is
then washed 5 times with 20 to 50 ml of acetone. The
precipitate is then dried under vacuum and then under a
stream of nitrogen.
The precipitate containing the derivatized
polysaccharide is taken up with an appropriate volume
of a solution of tetanus toxoid at 10 mg/ml in a 0.2 M
CA 02512847 2005-07-08
- 37 -
phosphate buffer, such that the derivatized
polysaccharide to tetanus toxoid weight ratio is
between 1 and 2. The mixture is incubated at laboratory
temperature, with stirring, for 16 to 20 hours. The
reaction is then stopped by precipitation with 70~
ammonium sulfate after 4-fold dilution of the mixture
in a 0.2 M phosphate buffer. The medium containing the
precipitate is stirred for 1 hour at laboratory
temperature and then for 4 to 20 hours at +4°C. After
having recovered the precipitate by centrifugation, it
is finally taken up and dissolved in a 0.2 M phosphate
buffer. The solution of the conjugate is obtained in a
virtually pure form. The amounts of unconjugated
tetanus toxoid and unconjugated polysaccharide are
l5 negligible. The solution is finally adjusted to the
desired concentration with a view to use for
immunization. The polysaccharide/protein ratio in the
conjugate is 1/5.
b) Study of the immunogenic capacity of the
conjugates
The immunogenic capacity of the conjugates thus
obtained is compared with that of a conjugate making
use of a pneumococcus type 5 capsular polysaccharide
subjected beforehand to a conventional reductive
amination, described as follows: the native
polysaccharide is first of all fragmented by free-
radical depolymerization according to the procedure of
paragraph a) of Example 1. A depolymerized
polysaccharide containing 30-35 repeating units is
obtained. The fragmented polysaccharide is then
subjected to a reductive amination according to the
procedure of paragraph b) of Example 2. The aminated
polysaccharide is then conjugated to tetanus toxoid via
DSS under the operating conditions of paragraph a) of
Example 3. The conjugate thus obtained has the same
characteristics of purity and can be used as a vaccine.
CA 02512847 2005-07-08
- 38 -
The polysaccharide/protein ratio in the conjugate is
1/5.
Fifteen NZB rabbits divided up into 3 different groups
are injected intramuscularly on days D1 and D23 with
one of the 3 polysaccharide conjugates, in a proportion
of 0.5 ~g of polysaccharide and 2.5 ~,g of tetanus
toxoid per rabbit and per injection.' Group 1 is
immunized with the conjugate obtained using the
aminated polysaccharide of Example 1, group 2 with the
conjugate obtained using the aminated polysaccharide of
Example 2, group 3 with the conjugate obtained using
the polysaccharide aminated according to a conventional
method, as described in the preceding paragraph of the
present example. A group of "control" rabbits is
injected intramuscularly with physiological saline on
D1 and D23.
Blood samples are taken on D1, D23 and D36 in order to
control these titers of serum antibodies specific for
the pneumococcus type 5 polysaccharide, by ELISA on
microplates coated with native pneumococcus type 5
polysaccharide (1 ~g/microwell). The antibody titers
contained in each rabbit are defined as being the
inverse of the serum dilution which gives an optical
density of 1 on a spectrophotometer subsequent to the
developing of the ELISA assay using a colored
indicator, trimethylbenzidine. The results are given in
Table I below:
Group D1 D23 D36
1 <10 239* (122-469)** 2824 (1758-4535)
2 <10 110 (74-164) 2929 (1180-7270)
3 ~ <10 57 (29-113) 423 (166-1078)
Control <10 <20 <20
*: represents the geometric mean of the specific
serum antibody titers of 5 rabbits
CA 02512847 2005-07-08
- 39 -
**: indicates the value of the lowest antibody titer
and the value of the highest antibody titer in each
group.
After two immunizations, the mean values of the
specific antibody titers of the rabbits immunized~with
conjugates obtained using the aminated polysaccharides
of Examples 1 and 2 are approximately 5 times higher
than that of the rabbits immunized with the conjugates
obtained using a polysaccharide aminated according to a
conventional method of reductive amination.
When the polysaccharide/tetanus toxoid weight ratios
are varied within a range of from 1/0.5 to 1/5, the
results which are obtained in the previously described
assays are similar in all respects.
The functionality of these antibodies is controlled
using an opsonophagocytosis assay. The opsonizing titer
is defined as being the inverse of the serum dilution
which makes it possible to kill 50% of the bacteria.
The results are given in Table II below:
Group D1 D23 D36
1 n.t. 7* (3-18)** 128 (27-599)
2 n.t. 2 (2-3) 185 (60-565)
3 n.t. 2 (1-5) 35 (11-110)
Control n.t. n.t. n.t.
*' represents the geometric mean of the opsonizing
titers of the 5 rabbits
**: indicates the value of the lowest opsonizing titer
and~the value of the highest opsonizing titer in each
group.
n.t.: not titered
CA 02512847 2005-07-08
- 40 -
The opsonizing titers correlate with the titers of
serum antibodies specific for the type 5 pneumococcus
polysaccharide.
